Citius Oncology, Inc.
CTOR · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $5 | $4 | $3 |
| G&A Expenses | $17 | $16 | $8 | $1 |
| SG&A Expenses | $17 | $16 | $8 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $24 | $21 | $12 | $5 |
| Operating Income | -$24 | -$21 | -$12 | -$5 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | -$24 | -$21 | -$12 | -$5 |
| Tax Expense | $1 | $1 | $1 | $1 |
| Net Income | -$25 | -$21 | -$13 | -$5 |
| % Margin | – | – | – | – |
| EPS | -0.34 | -0.3 | -0.19 | -0.076 |
| % Growth | -13.3% | -57.9% | -149% | – |
| EPS Diluted | -0.34 | -0.3 | -0.19 | -0.076 |
| Weighted Avg Shares Out | 73 | 72 | 89 | 90 |
| Weighted Avg Shares Out Dil | 73 | 72 | 89 | 90 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $3 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$23 | -$21 | -$12 | -$5 |
| % Margin | – | – | – | – |